Skip to main content

Advertisement

Table 5 Interventions in patients with or without autoimmune rheumatic disease who experienced a first myocardial infarction between 1 July 2001 and 30 June 2007 a

From: Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease

Variable Non-AIRD ( n= 77,981) AIRD ( n= 1,409) P -value Crude odds ratio (95% CI) P -value Adjusted odds ratio b (95% CI) P -value
PTCA       
  Within index MI admission 17,622 (22.6) 190 (13.5) <0.001 0.53 (0.46 to 0.62) <0.001 0.80 (0.68 to 0.94) 0.007
  Postdischarge and within 30 days of index MI episode 1,355 (2.2) 17 (1.4) 0.046 0.62 (0.36 to 0.99) 0.046 0.90 (0.56 to 1.44) 0.652
  Between 30 and 90 days of index MI episode 1,192 (2.0) 14 (1.2) 0.036 0.57 (0.31 to 0.97) 0.036 0.95 (0.55 to 1.66) 0.860
CABG        
  Within index MI admission 4,592 (5.9) 35 (2.5) <0.001 0.41 (0.29 to 0.57) <0.001 0.50 (0.35 to 0.70) <0.001
  Postdischarge and within 30 days of index MI episode 809 (1.1) 9 (0.7) 0.114 0.59 (0.27 to 1.13) 0.114 0.80 (0.43 to 1.51) 0.498
  Between 30 and 90 days of index MI episode 1,350 (1.9) 9 (0.7) 0.001 0.35 (0.16 to 0.67) 0.001 0.59 (0.30 to 1.15) 0.120
  1. aAIRD, Autoimmune rheumatic disease; CABG, Coronary artery bypass graft; CI, Confidence interval; MI, Myocardial infarction; PTCA, Percutaneous transluminal coronary angioplasty. bAdjusted for age, sex, Accessibility/Remoteness Index of Australia, Socio-Economic Indexes for Areas and Charlson comorbidities.